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low-gradient aortic stenosis: results from a multicentre
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The vast majority of patients with severe calcified aortic stenosis
(AS) have normal left ventricular (LV) ejection fraction, even in the
presence of symptoms.1 Nevertheless, ≈20% of patients with AS
and undergoing valve surgery were found with reduced LV ejection
fraction (,50%)1 in the last Euro Heart Survey. This characteristic is
often the result of a concomitant coronary artery disease. In some
patients, however, LV hypertrophy, due to the chronic pressure
overload, is inadequate to normalize systolic wall stress, resulting
in an afterload mismatch and a decrease in LV ejection fraction.2
Reduced LV function may lead to low-flow state and thus to low-
gradient, despite the presence of severe AS. In fact, three main
types of patients with severe AS, according to LV function and
flow, are generally observed: (i) normal LV ejection fraction and
normal flow, (ii) reduced LV ejection fraction and reduced flow,
and (iii) normal LV ejection fraction and reduced flow.
Low-ejection fraction/low-gradient severe AS represents a chal-
lenging clinical entity. The classification of patient in the so-called
low-flow/low-gradient (LF/LG) severe AS subset may considerably
vary from different studies and is generally based on the presence
of the three following haemodynamic criteria: (i) an aortic valve
area (AVA) ,1 cm2, (ii) a LV ejection fraction ,30–45%, and (iii) a
mean transvalvular pressure gradient (MPG) ,30–40 mmHg.3–12
LF/LG severe AS is associated with a poor outcome under conser-
vative management13 and a high operative mortality risk.14 More-
over, even after aortic valve replacement (AVR), the prognosis
of such patients is worse than those with preserved LV function,
and the improvement of symptoms remains limited.
True-severe or pseudo-severe
aortic stenosis
The reduced survival reported in LF/LG severe AS, when com-
pared with ‘classic’ severe AS, is obviously related to both the
LV disease and the inappropriate timing of surgery generally
reported in such patients. Indeed, due to the low-flow state, the
apparent discrepancy between AVA and MPG may be considered
as an artefact or a measurement error, which, in turn, could under-
estimate the severity of symptom and delay intervention. In this
regard, the cornerstone of the evaluation of LF/LG AS is the dis-
tinction between true- and pseudo-severe AS. In the former, the
aortic valve is really severely stenotic, the afterload mismatch is
the main cause of LV dysfunction, the symptoms are essentially
valve-related, and AVR is recommended and beneficial. In the
latter, the aortic valve could be only mildly or moderately stenotic
and the small reported AVA is due to an inability of the impaired
LV to generate enough forces to open the calcified aortic cups.
In this context, low-dose dobutamine stress echocardiography
(DSE) is strongly recommended for the assessment of such
patients. The DSE is crucial in the management of LF/LG AS15
and allows (i) as to distinguish true-severe from pseudo-severe
AS3,12 and (ii) to evaluate the presence of LV contractile reserve,
which is a marker of better peri-operative outcome.6,7 During
dobutamine infusion, a pseudo-severe AS may increase its AVA
and only exhibits small changes in MPG. In contrast, true-severe
AS had no or minimal augmentation in AVA during DSE and had
a marked increase in MPG.
Nevertheless, in the presence of an excessive LV afterload, with
no or few LV contractile reserve (≈one-third of patients), the nor-
malization of flow rate is not possible and, unmasking pseudo-severe
AS is challenging. In this regard, the calculation of the projected AVA
at a normal transvalvular flow rate (Qmean . 250 mL/s) may be very
useful and more accurate than the traditional echocardiographic
indices (e.g. valvular resistance, dobutamine-induced increase in
AVA, or MPG) to differentiate true from pseudo-severe AS.5
Global left ventricular afterload
Concomitantly to the progressive aging of the general population,
AS is nowadays becoming a part of the general atherosclerotic
disease process, which progressively decreases the compliance of
the vascular bed downstream the aortic valve. Besides the LV dys-
function, LF/LG AS is often associated with concomitant systemic
hypertension.5,16,17 This may induce a low-flow state despite
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normal LV ejection fraction. As a result, the LV faces a double
afterload: (i) a valvular load, due to the AS and (ii) an arterial
load, as a consequence of reduced arterial compliance.
The valvuloarterial impedance (Zva) is a new index proposed by
the group of Pibarot and coworkers,18 assessing the global LV
haemodynamic load (i.e. total load) that can be measured by
Doppler echocardiography. The Zva is defined as the ratio of
the estimated LV systolic pressure [i.e. the sum of systolic arterial
pressure (SAP) and MPG] to the stroke volume indexed (SVi) for
body surface area: Zva = (SAP+MPG)/SVi. This index in fact
represents the valvular and arterial factors that oppose ventricular
ejection by absorbing the mechanical energy (transformed in heat)
developed by the LV.
The Zva is associated with LV myocardial dysfunction,19 and
with longitudinal, radial, and circumferential LV deformation
impairment,20 especially in low-flow patients. Of note, the LV of
patients with moderate AS and concomitant hypertension may
face a global haemodynamic load equivalent, or even superior,
than patients with severe AS but no hypertension. In this regard,
patients may probably develop myocardial dysfunction and symp-
toms because of the combination of moderate AS and some
degrees of hypertension.
The concept of ‘global afterload’ emerges as appealing and, in a
clinical standpoint, may be very useful to reconcile the apparent
discordance between moderate AS and the symptomatic status.
In the case of a low Zva, the symptoms may be related to
another concomitant disease. On the contrary, in high-Zva
patients, the symptoms could be the result of the additive effects
of a moderate AS and reduced arterial compliance and/or
increased vascular resistance.
Furthermore, as expected, high Zva is associated with a poorer
outcome.21 Retrospectively, Hachicha et al.22 found a graded
relationship between increased Zva and reduced overall survival.
In addition, we recently found that high Zva (≥5 mmHg/mL m2)
was a powerful predictor of reduced cardiac event-free survival





The study by Levy et al.23 was aimed to evaluate the prognostics
value of Zva in patients with low-ejection fraction, low-gradient
severe AS. From 1995 to 2005, consecutive symptomatic patients
with severe LF/LG AS who underwent DSE were included in this
French multicentre registry. The Zva was retrospectively calculated
in 184 patients (71+10 years, 75% of male) and confronted to
other demographic or echocardiographic parameters in predicting
the outcome. A total of 88 patients (48%) had a high Zva
(≥5.5 mmHg/mL/m2). Compared with the low-Zva group, these
patients had more severe AS, significant lower ejection fraction
and LV end-diastolic diameter, and had more frequently a contrac-
tile reserve. Based on a DSE-induced increase in AVA ≥0.3 cm2
associated with a peak DSE AVA ≥1 cm2, pseudo-severe AS was
found in 12% of the cohort. Interestingly, the Zva value was stat-
istically similar between true and pseudo-severe AS and therefore,
was not helping to discriminate these patients.
As previously published,19–21 the authors reported a significant
association between reduced LV function and increased Zva. They
elegantly found that this relationship seems to be more pro-
nounced in patients with very low LV ejection fraction (,20%).
In the whole cohort, a high Zva was not associated with 5-year
reduced survival. In addition, in the subset of patients who were
operated on, Zva was not predictive of both operative and
5-year post-operative mortality.
The authors concluded that, by opposition to LV contractile
reserve, Zva had no prognostic value and seems to be useless
for predicting mid-term survival and both operative and 5-year
post-AVR mortality.
However, the lack of relationship between Zva and outcome in
LF/LG severe AS might be explained, in part, by fluid mechanics.
Valvuloarterial impedance: a
flow-dependent parameter
By nature, Zva is flow-dependent and may considerably vary in a
same patient over time and during an echocardiographic examin-
ation, more specifically in the presence of low-flow state. More-
over, two patients with similar AVA and degree of hypertension
(i.e. similar LV global afterload), may have different Zva values.
The MPG (included in the numerator of the equation for the cal-
culation of Zva) is highly flow-dependent and had a square
relationship with the Qmean. Because the SVi is the only par-
ameter included in the denominator, the impact of flow on the
variability of Zva is more important in low-flow state than in a
normal or high-flow situation. Subtle changes in SVi and in heart
rate may result in high variation in Zva in LF/LG patients
(Figure 1). In addition, the impact of minor error in the measure-
ment of SVi on the calculation of Zva may be stronger in
low-flow patients. The weak correlation reported by the authors
between Zva and MPG confirms that these two parameters are
subject to broad variability.
Under dobutamine, a small increase in Qmean may rapidly and
noticeably decrease Zva. In patients with low-ejection fraction and
low-flow, the Qmean may also markedly vary over patients, from
very low (,100 mL/s) to quite normal (.250 mL/s). As empha-
sized in Figure 2, the Zva calculated for a patient with severe AS
(AVA ¼ 0.7 cm2) considerably varies according to the flow. Inter-
estingly, this simulation is obtained with a constant SAP
(120 mmHg), as it is often the case in low-flow patients due to
the adaptation of vascular resistance, suggesting that the variability
of Zva is not only related to the changes in SAP. Furthermore, the
extent of the flow dependency is higher in low-flow state (SV
,60–50 mL). While Zva rises by only 10% between 120 and
60 mL of SV, the increase in low-flow state is very high (.45%).
This observation suggests that the calculation of Zva in LF/LG
AS is less accurate for estimating the LV global haemodynamic
load. Zva was previously found to be associated with a poor
outcome in a large series of patients with AS and preserved LV
function.21,22 Hence, as highlighted by the results of Levy et al,23
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it might be argued that the presence of poor LV function rep-
resents the main determinant of outcome in LF/LG severe AS.
The outcome of such patients thus seems to relate more to the
intrinsic LV myocardial dysfunction than to the global LV haemo-
dynamic burden.
The authors reported no statistical differences in Zva between
pseudo and true-severe AS. Figure 2 revealed that the Zva is mark-
edly lower in pseudo than in true-severe AS patients when the SV
is .60 mL. On the other hand, for a SV ,50 mL, Zva are very
similar in both groups. This may also explain why Zva is not accu-
rate to distinguish pseudo-severe from true-severe AS. This obser-
vation also strengthens the idea that Zva at rest might not be a
good parameter to evaluate the global LV haemodynamic burden
in LF/LG AS. Thus, the use of peak DSE or DSE-induced changes
in Zva might be of more interest.
Conclusion
To improve the risk stratification and the management of AS,
which remains challenging in numerous cases, the comprehensive
evaluation of the valvular and arterial load is mandatory. In this
regard, the calculation of Zva appears as particularly useful.
However, in LF/LG AS, the Zva seems to be less precise in the
assessment of the LV global afterload, essentially due to its high-
flow dependency in this specific subset of patient.
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Figure 1 Doppler echocardiographic measurements in a patient with low-flow/low-gradient severe aortic stenosis. Resting indexed aortic
valve area was 0.35 cm2/m2 and increased up to 0.5 cm2/m2 under 10mm/kg/min of dobutamine infusion. Systolic arterial pressure remained
unchanged during the test. The normalization of transvalvular flow rate (Qmean) during dobutamine stress echocardiography resulted in a
significant decrease in valvuloarterial impedance (Zva). SVi indicates indexed stroke volume and MPG, mean pressure gradient.
Figure 2 Simulation of the relationship between valvuloarterial
impedance and left ventricular stroke volume in patients with
true-severe (aortic valve area ,0.7 cm2) and pseudo-severe
aortic stenosis. In low-flow state (stroke volume ,50 mL),
(i) the Zva markedly increased in response to small changes in
stroke volume, and (ii) true- and pseudo-severe aortic stenosis
exhibited similar Zva. Body surface area was assumed at 1.8 m2,
left ventricular end-diastolic volume at 120 mL, heart rate at
65 b.p.m., and systolic arterial pressure at 120 mmHg.
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